Drug Profile
BIO 130
Alternative Names: BIO-130Latest Information Update: 25 Mar 2008
Price :
$50
*
At a glance
- Originator Molecular Insight Pharmaceuticals
- Class Imaging agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cerebrovascular disorders
Most Recent Events
- 02 Nov 2005 No development reported - Preclinical for Imaging of Cerebrovascular disorders in USA (unspecified route)
- 21 Jan 2003 Preclinical trials for Imaging of Cerebrovascular disorders (unspecified route)